Phase 2 Lymphoma Trial, Recruiting NCT04747912 Sponsor: University of Chicago Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT04747912
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been recently diagnosed with a specific type of blood cancer called Ph+ B-cell Acute Lymphoblastic Leukemia (ALL) and have not yet received treatment for it, with a certain protein (CD22) present on at least 20% of your cancer cells.
  • You are 18 years of age or older.
  • Your bone marrow testing shows at least 20% cancer cells, along with a specific genetic marker confirmed by laboratory testing; or, if a bone marrow biopsy is not possible due to your condition, you have a high enough number of cancer cells in your blood to confirm the diagnosis.
  • You are generally able to carry out daily activities, with only mild limitations at most (confirm with trial site).
  • Your heart, liver, kidneys, and other organs are working well enough as shown by medical tests.
  • It has been at least 2 weeks since any major surgery, radiation, or participation in another clinical trial, and you have recovered from any significant side effects from those treatments.
  • You are willing and able to sign a consent form agreeing to take part in the study.
  • If you are a woman who could become pregnant, you agree to use effective birth control during the treatment and for at least 8 months after your last dose of the study drug.
  • If you are a man with a female partner who could become pregnant, you agree to use effective birth control during treatment and for at least 5 months after your last dose of the study drug.
  • You are willing and able to attend scheduled visits, follow the treatment plan, and complete all required tests and procedures.

Who may not be able to join:

  • Your leukemia is only found outside of the bone marrow and is not affecting the bone marrow itself.
  • You have been diagnosed with a different type of leukemia called Burkitt's or mixed-lineage leukemia.
  • Your leukemia has spread to your brain or spinal fluid (central nervous system).
  • You have already received treatment for ALL, except for a short course (7 days or fewer) of certain steroids or a specific medication, or a single dose of chemotherapy given directly into the spinal fluid; people taking long-term steroids for other conditions (such as asthma) may still be eligible.
  • You currently have or have had a chronic hepatitis B or C infection, or are HIV-positive with a detectable viral load (those with HIV but an undetectable viral load may still be eligible).
  • You had major surgery within the last 2 weeks before joining the study.
  • You have an unstable or serious uncontrolled medical condition, such as heart or lung problems.
  • You currently have another type of cancer, unless it is a minor skin cancer, early-stage cervical cancer, or prostate cancer already fully treated — or you had a previous cancer but have been cancer-free for at least 2 years and are not currently receiving treatment for it.
  • You have uncontrolled heart disease.
  • Your heart's electrical activity (measured by an ECG) shows a reading above a certain level (confirm with trial site).
  • You have a history of chronic liver disease (such as cirrhosis) or suspected alcohol misuse.
  • You have a history of a serious liver condition involving blocked blood vessels in the liver (confirm with trial site).
  • You currently have a serious active infection (such as blood poisoning) or have had a severe deep tissue infection (such as a bone infection) within the last 4 months.
  • You are taking certain medications known to affect heart rhythm in a specific dangerous way (confirm with trial site for specific medications).
  • You are pregnant or breastfeeding, or are not willing or able to use effective contraception as required by the study.
  • You work at the trial site, are a close relative of someone who does, or are a Pfizer employee directly involved in running this trial.
  • You are currently taking part in another clinical trial during the active treatment period of this study.
  • You have any other serious medical, mental health, or laboratory condition that the lead doctor believes could put you at greater risk or affect the study results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Wendy Stock, MD, University of Chicago

Phone: 1-855-702-8222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
2 March 2021
Est. completion
1 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants Who Enter Complete Clinical Remission at 60 Days as Defined by Criteria Set By The International Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov